TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3360270
Drug: Paracentesis plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracentesis plus intravenous albumin infusion (40 g after each tap)
Study: 3360270
Drug: Paracentesis without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracentesis without intravenous albumin infusion
Study: 26331821
Drug: Icotinib hydrochloride
Normalized name: Nicotine
DrugBank: Icotinib (DB11737)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icotinib hydrochloride 150 mg every 12 hours
Study: 26331821
Drug: Icotinib hydrochloride
Normalized name: Nicotine
DrugBank: Icotinib (DB11737)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icotinib hydrochloride 200 mg every 12 hours
Study: 26331821
Drug: Icotinib hydrochloride
Normalized name: Nicotine
DrugBank: Icotinib (DB11737)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icotinib hydrochloride 125 mg every 8 hours
Study: 26331821
Drug: Icotinib hydrochloride
Normalized name: Nicotine
DrugBank: Icotinib (DB11737)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icotinib hydrochloride (various doses)
Study: 21959663
Drug: Anterior positioning
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior positioning splint therapy (group I)
Study: 21959663
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy in addition to splint therapy (group III)
Study: 18303526
Drug: Loop diuretics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics, nitrates, inotropes (dobutamine, milrinone)
Study: 18303526
Drug: Vasoactive drugs
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive drugs
Study: 2052631
Drug: Acu‐ES group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acu‐ES group (electrical stimulation applied to four antihypertensive acupuncture points)
Study: 6315775
Drug: Naltrexone (opiate-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (opiate-receptor antagonist)
Study: 29575717
Drug: Antifungal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal therapy (terbinafine, fluconazole, itraconazole, voriconazole, or posaconazole) for 4 to >12 weeks with standard bronchodilator and anti-inflammatory agents
Study: 29575717
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without antifungals
Study: 26223423
Drug: SLActive Bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLActive Bone level implant (Institut Straumann AG, Basel, Switzerland)
Study: 26223423
Drug: CMI IS‐II
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMI IS‐II active implant (Neobiotech Co., Seoul, Korea)
Study: 17602086
Drug: gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine 1,000 mg/m2 (days 1 and 8; every 21 days)
Study: 17602086
Drug: PLD 50
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 50 mg/m2 (day 1; every 28 days)
Study: 14996349
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no lamivudine therapy)
Study: 9509971
Drug: G‐CSF started
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF started on day 0
Study: 9509971
Drug: G‐CSF started
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF started on day +3
Study: 9509971
Drug: G‐CSF started
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF started on day +5
Study: 7800170
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg perazine
Study: 27073832
Drug: Whole Body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Body Vibration (WBV) therapy, 15 minutes of intermittent vibration, performed twice per week for three months.
Study: 20363089
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of Addiction to Nicotine in Schizophrenia (TANS)
Study: 20363089
Drug: Medication Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Management (MM)
Study: 18766258
Drug: PEGLip‐rFVIII‐FS reconstituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGLip‐rFVIII‐FS reconstituted with 4.2 mg/kg of pegylated liposomes
Study: 18766258
Drug: PEGLip‐rFVIII‐FS reconstituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGLip‐rFVIII‐FS reconstituted with 12.6 mg/kg of pegylated liposomes
Study: 18766258
Drug: PEGLip‐rFVIII‐FS reconstituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGLip‐rFVIII‐FS reconstituted with 22.1 mg/kg of pegylated liposomes
Study: 15998278
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment with adjunctive doxycycline (100 mg/day for 15 days)
Study: 15998278
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal treatment without doxycycline
Study: 12706919
Drug: B-type natriuretic
Normalized name: B-type natriuretic peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-type natriuretic peptide (BNP) >80 pg/ml
Study: 1944976
Drug: Postoperative anti-platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative anti-platelet therapy with ASA and dipyridamole
Study: 1944976
Drug: Postoperative anti-platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative anti-platelet therapy with indobufene
Study: 31868691
Drug: Basic care
Normalized name: Basic Care Miconazole KIT
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basic care of the face and mouth plus treatment as usual
Study: 28586638
Drug: Paracetamol 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1,000 mg, Ibuprofen 400 mg, Codeine 60 mg
Study: 28586638
Drug: Paracetamol 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1,000 mg, Ibuprofen 400 mg
Study: 24569618
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg daily for 12 weeks
Study: 17055685
Drug: Doxazosin mesylate
Normalized name: Doxazosin Mesylate
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxazosin mesylate (4 mg single dose)
Study: 9698717
Drug: Mebendazole 500
Normalized name: mebendazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole 500 mg single-dose treatment
Study: 9698717
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg single-dose treatment
Study: 8550163
Drug: Conventional plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional plaster treatment
Study: 20889882
Drug: Age less
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age less than 18 months (independent of treatment)
Study: 19439966
Drug: 2.3 g
Normalized name: Urea 2.3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.3 g omega-3 fatty acids daily for 6 months
Study: 11694151
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive treatment strategy (n = 1222)
Study: 11694151
Drug: Noninvasive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive treatment strategy (n = 1235)
Study: 8275889
Drug: Phenothiazine (chlorpromazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenothiazine (chlorpromazine 350 mg)
Study: 8275889
Drug: Butyrophenone (haloperidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butyrophenone (haloperidol 15 mg)
Study: 8275889
Drug: Anticholinergic agents
Normalized name: ANTICHOLINERGIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic agents (trihexiphenidyl, 5 mg)
Study: 22743314
Drug: Inulin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (20 g/d, 3 times/d for 4 weeks)
Study: 17373724
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of caffeine per day
Study: 9689291
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of methyl nicotinate (vasodilator)
Study: 2686425
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin (200 mg every 12 hours, plus a daily extra placebo dose)
Study: 30266711
Drug: S1 pedicle
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: S1 pedicle screw with PMMA augmentation (group A)
Study: 8566592
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of H. pylori eradication and acid suppression
Study: 1937545
Drug: MCP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCP plus oral lorazepam (1 mg/d)
Study: 1937545
Drug: MCP (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCP (0.5 mg/kg 6 hourly i.v.)
Study: 7035638
Drug: Intravenous alimentation
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alimentation with a solution containing carbohydrate as 50% glucose and 50% galactose
Study: 27931142
Drug: Orafti® inulin‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orafti® inulin‐type fructans (2g daily for 6 weeks)
Study: 19777799
Drug: Arginine supplementation
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine supplementation at 0.1 g/kg‐wt
Study: 11407108
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa antagonists
Study: 23656707
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (50 g available carbohydrate)
Study: 23656707
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral glucose and white bread
Study: 21942436
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg oral daily)
Study: 16895950
Drug: T+DMPA (testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: T+DMPA (testosterone implant + depot medroxy progesterone acetate)
Study: 16895950
Drug: T+DMPA+FSH (testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: T+DMPA+FSH (testosterone implant + depot medroxy progesterone acetate + follicle-stimulating hormone)
Study: 16895950
Drug: T+DMPA+hCG (testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: T+DMPA+hCG (testosterone implant + depot medroxy progesterone acetate + human chorionic gonadotropin)
Study: 15204675
Drug: Buprenorphine-naloxone taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine-naloxone taper regimen for short-term opioid detoxification
Study: 15204675
Drug: Buprenorphine-naloxone taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine-naloxone taper regimen
Study: 11556635
Drug: Mecamylamine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (2.5 to 7.5 mg/day)
Study: 3027905
Drug: Lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20 mg/d)
Study: 3027905
Drug: Lisinopril plus
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril plus Hydrochlorothiazide (HCTZ)
Study: 31581743
Drug: High green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: High green leafy vegetable (GLV) dietary intervention, one cooked cup equivalent daily for 4 weeks
Study: 28213170
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Mirtazapine + SSRIs)
Study: 28213170
Drug: SSRIs monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs monotherapy
Study: 21496149
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous (IV) insulin infusion
Study: 19954075
Drug: Domestic split
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic split influenza virus vaccine (study group)
Study: 19954075
Drug: Imported vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported vaccine (control group 1)
Study: 19954075
Drug: Imported vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported vaccine (control group 2)
Study: 14660311
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and topical lidocaine‐prilocaine cream (EMLA)
Study: 14660311
Drug: Ketamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine and topical placebo cream
Study: 9211479
Drug: Capsaicin (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (0.03 mg/ml, 20 microliters applied topically for 30 min)
Study: 20716255
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg once daily for 14 days
Study: 20716255
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once daily plus metronidazole 500 mg twice daily for 14 days
Study: 2290163
Drug: Subacromial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial injection of triamcinolone
Study: 2290163
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac 50 mg TDS
Study: 22086300
Drug: 40 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 μg vitamin D(3) plus 1,000 mg calcium per day
Study: 22086300
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg calcium per day (Control)
Study: 19292654
Drug: Bofu‐tsusho‐san (BTS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bofu‐tsusho‐san (BTS) 7.5 g/day
Study: 19292654
Drug: Placebo of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of BTS 7.5 g/day
Study: 19292654
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 500 mg and Vitamin C 1000 mg/day
Study: 11594439
Drug: Hydromorphone (1.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (1.5, 3, and 6 mg/70 kg)
Study: 11594439
Drug: Butorphanol (1.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (1.5, 3, 6, and 12 mg/70 kg)
Study: 184377
Drug: N 041
Normalized name: (Alginate)n
Approvals — FDA: no, EMA: no, PMDA: no
Description: N 041 (essential phospholipids in combination with Clofibrate)
Study: 23021878
Drug: Omalizumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (4 to 8 subcutaneous doses, n = 16)
Study: 19624838
Drug: Cineole 200
Normalized name: Cineole
DrugBank: Eucalyptol (DB03852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cineole 200 mg, 3 times daily for 6 months
Study: 17114212
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (10 sessions over five weeks)
Study: 9140801
Drug: moexipril 7.5
Normalized name: moexipril 7.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: moexipril 7.5 mg/HCTZ 12.5 mg
Study: 9140801
Drug: metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol 100 mg/HCTZ 12.5 mg
Study: 2142246
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg toremifene daily
Study: 2142246
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg toremifene daily
Study: 30558968
Drug: Chlorhexidine-impregnated gel
Normalized name: chlorhexidine Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine-impregnated gel dressing
Study: 26506580
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) delivered over 14 sessions for 4 months
Study: 26506580
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition consisting of written psycho-education materials and weekly telephone monitoring
Study: 21846154
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg (titrated to 300 mg after 6 weeks)
Study: 19542517
Drug: 1SMS (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1SMS (one weekly SMS feedback)
Study: 19542517
Drug: 3SMS (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3SMS (three weekly SMS feedbacks)
Study: 17287682
Drug: Facilitated PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated PCI (immediate planned PCI after i.v. thrombolytic therapy)
Study: 11527067
Drug: Qi therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi therapy (QT)
Study: 8840055
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml normal saline (Control Group P)
Study: 31072566
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg plus aspirin
Study: 26831333
Drug: 1% linalool
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% linalool inhalation
Study: 25233668
Drug: Photoelectric combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photoelectric combined with musical treatment (group A)
Study: 25233668
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch tablet, group C)
Study: 17925627
Drug: Sexual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sexual therapy group (n=47)
Study: 15756442
Drug: Irinotecan 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 125 mg/m2, FA 20 mg/m2 followed by 5‐FU 500 mg/m2 bolus, weekly for 4 weeks (arm A)
Study: 15756442
Drug: Irinotecan 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 350 mg/m2 alternating with FA 20 mg/m2/day followed by 5‐FU bolus 425 mg/m2/day for 5 days (arm B)
Study: 15756442
Drug: FA 20
Normalized name: INPEFA 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: FA 20 mg/m2/day followed by 5‐FU bolus 425 mg/m2/day over 5 days every 4 weeks (arm C, Mayo Clinic regimen)
Study: 8559001
Drug: Fordtran solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fordtran solution (polyethylene glycol solution)
Study: 8559001
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution (whole-gut lavage)
Study: 7018164
Drug: Tinidazole 2
Normalized name: tinidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 2 g single oral dose given to females with treated partners
Study: 19036903
Drug: nab-paclitaxel (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (260 mg/m² q3wk)
Study: 19036903
Drug: docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel (100 mg/m² q3wk)
Study: 19036903
Drug: paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: paclitaxel (175 mg/m² q3wk)
Study: 15469651
Drug: DHA-rich oil
Normalized name: Ulkenia DHA oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich oil (4.9 g DHA/d)
Study: 15469651
Drug: EPA-rich oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-rich oil (4.8 g EPA/d)
Study: 3555650
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with chlorambucil and prednisone (CP)
Study: 29619838
Drug: L-homoarginine (L-hArg)
DrugBank: L-homoarginine (DB03974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-homoarginine (L-hArg) levels
Study: 25122097
Drug: Task-oriented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-oriented therapy with personalized resistance (TOT_ST group)
Study: 25122097
Drug: Task-oriented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-oriented therapy without load (TOT group)
Study: 22921881
Drug: Statin discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin discontinuation
Study: 20804498
Drug: Pralidoxime (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pralidoxime (700 mg)
Study: 20804498
Drug: Pralidoxime (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pralidoxime (350 mg), Atropine (2 mg), Avizafone (20 mg)
Study: 15705641
Drug: Teicoplanin 400
Normalized name: Teicoplanin 400 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 400 mg every 12 h
Study: 7637721
Drug: Intravenous ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ganciclovir (5 mg/kg daily)
Study: 7637721
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (3000 mg daily)
Study: 2692819
Drug: Naproxen (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (375 mg orally, twice daily)
Study: 832528
Drug: Fosfomycin, total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin, total dose of 4 g (2g/4h)
Study: 832528
Drug: Fosfomycin, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin, single dose of 4 g (2 g in each buttock)
Study: 832528
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 4 g (control for failures)
Study: 29719302
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bevacizumab (10 mg/kg IV every 14 days) and Erlotinib (150 mg orally daily)
Study: 29719302
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bevacizumab and Erlotinib
Study: 29719302
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bevacizumab and Erlotinib among Child‐Pugh class A patients
Study: 12143912
Drug: Direct switch
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct switch to olanzapine (10 mg/day for 6 weeks)
Study: 12143912
Drug: Start‐taper switch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start‐taper switch to olanzapine (10 mg/day for 6 weeks) with decreasing doses of usual antipsychotic for first 2 weeks